Septerna (SEPN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.29
- Estimate
- -$0.49
- Surprise
- +41.2%
- Revenue (period 2026-06-30)
- $26.7M
- Score today
- 4.6/10
Revenue source: xbrl.
How the report landed
Septerna (SEPN) reported a narrower loss than forecast — adjusted EPS of -$0.29 against the -$0.49 estimate (a 41.2% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SEPN Sell at 4.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +41.2% surprise compares with a -5.7% four-quarter average. Next scheduled report: 2026-11-09.
What supports the rating
- Sector modifier (Healthcare): +0.5
What argues against it
- Thin upside margin: 4.7%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $45.06
- Price target
- $47.17
- Stop
- $41.91
- Upside to target
- +4.7%
- Reward-to-risk
- 0.3:1
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
SEPN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.07B
- P/E (fwd)
- -22.8
- 52-week range
- $17.55–$51.10
- Off 52-week high
- 11.8%
- RSI (14)
- 74
- Volume vs avg
- 0.02×
- Score today
- 4.6/10